NG101 antibody restores nerve regeneration following spinal cord injury

The NG101 antibody, designed to inhibit Nogo-A—a potent suppressor of axonal growth in the central nervous system—has demonstrated the ability to slow structural degeneration of the spinal cord following traumatic injury and promote nerve fiber regeneration in humans. Using multimodal MRI imaging, researchers measured both macroscopic and microstructural changes in NG101-treated versus placebo participants, finding faster lesion volume reduction and slower decline in myelin density within corticospinal tracts in the treatment group. This represents one of the first clinical trials combining imaging biomarkers with electrophysiological measures to detect genuine neuroregenerative effects in incomplete cervical spinal cord injury. For longevity-conscious readers, these findings suggest that selective blockade of axonal growth suppressors offers a viable therapeutic pathway to restore motor function months after initial injury—potentially transforming outcomes for patients previously considered non-recoverable.